Clinical Imaging Research Centre in Kooperation mit Siemens Medical Solutions in Singapur

Singapur, (PresseBox) - Die National University of Singapur und A*STAR (Agency for Science, Technology and Research) gaben heute die Eröffnung eines neuen Clinical Imaging Research Centres in Singapur bekannt. Ziel des Forschungszentrums ist, klinische Forschungen im Bereich der Biomedizin zu fördern, vor allem im Bereich "Biomedical Imaging", eines der innovativsten Instrumente zur Diagnose und Bestandsaufnahme bei Patienten. Die Forschungen werden in Kooperation mit Siemens Medical Solutions, dem deutschen Forschungs-Kompetenzzentrum in Singapur, durchgeführt.
----------------------------------------
Pressemitteilung:

A*STAR and NUS establish new Clinical Imaging Research
Centre with Siemens as industry partner
A new Clinical Imaging Research Centre (CIRC) will be set up by the Agency
for Science, Technology and Research (A*STAR) and the National University
of Singapore (NUS) to undertake clinical research and advanced biomedical
imaging in humans using an extensive suite of state-of-the-art imaging tools
from German technology powerhouse, Siemens Medical Solutions.
The centre will be one of the few clinical research sites in the world to use the
MR-PET, an innovative advanced medical imaging solution being developed
by Siemens. It will combine two powerful leading edge imaging techniques of
3-Tesla Magnetic Resonance Imaging (3T MRI) with Positron Emission
Tomography (PET). The centre will start with the 3T MRI system, and
subsequently the PET system will be introduced. 3T MRI provides detailed
anatomical images and measures of physiological function while PET systems
provide molecular details of cellular functions. By conducting both scans
simultaneously with the MR-PET, clinical researchers would be able to define
and locate diseases accurately while identifying underlying molecular causes.
The ability to study disease pathways can be used for the development of
new drugs and therapies.
Said Mr Lim Chuan Poh, Chairman of A*STAR, “The introduction of powerful
clinical imaging research capabilities into Singapore will be a major boost to
advancing clinical and translational research. A*STAR’s joint venture with
NUS and our partnership with Siemens will strengthen the connection
between ‘bench and bedside’. The research, capabilities and infrastructure at
the Centre will accelerate the advancement of science, positively impact
patient care and treatment, and create new opportunities for industry to
collaborate with the public sector and tertiary institutions.”
The CIRC will be a focus for development and validation of new imaging
methods as well as enable the study of novel interventions in humans. The
centre is dedicated to research and will focus on key disease areas of
particular relevance to Singapore and the health of its population, such as
cancer, neurodegenerative disorders and other diseases.
As part of the partnership, Siemens will set up a research foundation grant of
US$2.5 million over five years to support collaborative research in
translational medicine at the CIRC.
CIRC will be led by Professor Sir George Radda, Chairman of the Singapore
Bioimaging Consortium of A*STAR. Prof Radda will head a CIRC
management committee comprising Professor John Wong, Dean of the Yong
Loo Lin School of Medicine and Vice President for Research/Life Sciences at
NUS; Professor Judith Swain, Executive Director of the Singapore Institute of
Clinical Sciences, A*STAR, and Dr Beh Swan Gin, Executive Director of the
Biomedical Research Council, A*STAR.
The Management Committee is in the process of recruiting a Director to be
jointly appointed by A*STAR and NUS to head CIRC. The Centre will also
establish four medical teams each led by a principal investigator with a group
of post-doctoral fellows and a highly specialised technical team.
CIRC will initially be based in the NUS Centre for Life Sciences Building
located adjacent to A*STAR’s Singapore Institute for Clinical Sciences and
the National University Hospital. CIRC will eventually be housed in a new
building at the NUS Yong Loo Lin School of Medicine. This strategic location
will enable CIRC to capitalize on the rich clinical research milieu and to foster
greater collaborative efforts with the universities, research institutes, hospitals,
and specialty centers. The Centre will also work closely with the industry
partners such as Siemens and others.
Professor John Wong said, “This strategic collaboration with A*STAR and
Siemens is indeed a significant milestone for NUS and Singapore. As a
comprehensive University with significant expertise and interest in the Life
Sciences, developing novel ways to image the human body will mobilize talent
across many Faculties and Schools, particularly in Engineering, Science,
Medicine, Computer Science, and Dentistry. We will be working closely with
the National University Hospital and NUS Enterprise to develop even more
strategic relationships with research and industry partners to translate
discoveries into medical applications that will benefit Singaporeans and the
rest of the world.”
Professor Radda said, “Clinical imaging capabilities and research is highly
integrative and collaborative nature. We want to develop CIRC into a major
clinical research imaging centre in Asia and a national resource for research
and training in the R&D community. CIRC catalyses scientific and medical
advances and stimulate industry growth by putting very powerful capabilities
into the hands of biomedical and clinical investigators from both the private
and public sector. Clinical imaging holds major potential benefit to patients.”
“We are committed to transferring highly qualified personnel to Singapore’s
radio-biomarker discovery program,” said Mr Michael Reitermann, President
of Siemens Medical Solutions, Molecular Imaging division. “This is an
important step towards Siemens’ vision to expand and develop new
technologies to help ensure affordable personalized medicine is within reach
of a wider population.”
The CIRC aims to undertake world-class research using state of the art
imaging tools and technologies, provide a shared resource for research
imaging across Singapore, and be a focal point for the development, testing
and validation of new imaging methods, biomarkers and imaging agents for
human studies. The multimodality and multidisciplinary research centre will
have a focus on specific areas of biomedical research, including clinical trials,
novel medical devices and validation work. It is designed and organized to
support translational and clinical research by bringing together basic scientists
and clinicians who are keen to study the impact of new therapies and devices
in human patients. It also aims to be a major training centre for Masters and
PhD students in clinical imaging.
“Siemens is honored to be a technology partner in this long-term
collaboration,” said Mr. Hans-Dieter Bott, Country Manager of the Siemens
Group of Companies in Singapore. “The government’s commitment and
support of this public-private sector initiative to build an international center of
excellence in biotechnology makes Singapore a great investment location for
Siemens.”
“As part of our efforts to establish Singapore as the Asian thought leader in
biomedical sciences research, EDB strongly promotes technology companies
to form partnerships with the public research community in Singapore to
leverage on the scientific excellence and capabilities that we have built here.
The collaboration between NUS, A*STAR and Siemens is a very good
example of a successful public private partnership." said Mr Yeoh Keat Chuan,
Executive Director, Biomedical Sciences Group, Economic Development
Board.
“The Clinical Imaging Research Centre is a key scientific infrastructure that
reinforces our translational research efforts, supporting clinical trials and the
development of novel medicines and devices," Mr Yeoh added.

Im Auftrag des Economic Development Board,
Lale Karahan
Hotwire
069- 25 66 93 85

EDB Singapore- Economic Development Board of Singapore

Über das Singapore Economic Development Board (Singapore EDB)
Das Singapore EDB ist Singapurs leitende Behörde für internationale Investitionen. Sie verantwortet die Planung und die Ausführung von Strategien für die Stärkung von Singapurs Position als globale Investitionsdrehscheibe.

Das Singapore EDB arbeitet eng mit den lokalen und ausländischen Unternehmen zusammen und betreut mit ihnen zusammen eine Vielzahl von verschiedenen Aktivitäten. Durch diese Zusammenarbeit im Dienstleistungs- sowie Fertigungssektor unterstützt er Unternehmen, in einer zunehmend auf Wissen und Innovation basierenden Umgebung, eine höhere Wertschöpfung zu erzielen. Die Behörde ermutigt Unternehmen darin, Singapur als Firmensitz und Geschäftszentrum für globale und regionale Aufgaben hinsichtlich ihrer weltweiten und asiatisch-pazifischen Aktivitäten zu nutzen.

Singapur ist heute eine „Global Entrepolis“ – ein einzigartiger Marktplatz an dem Geschäfte abgeschlossen, Fonds erhöht, kreative Ideen ausgetauscht und umgesetzt sowie neue innovative Unternehmen gegründet und Partnerschaften geschlossen werden. Das Singapore EDB wirkt als Katalysator und Vermittler für ein gedeihendes „Unternehmensökosystem“. Es ermutigt Innovation und Unternehmergeist indem es ein Umfeld schafft, das Start-Ups und Unternehmen aller Größen dazu anhält, gemeinsam zu interagieren. Das Singapore EDB schafft damit einen Standort, in dem Unternehmen durch gute Unternehmensführung und unter Schutz ihres geistigen Eigentums wachsen können.

Weitere Informationen über das Singapore EDB und wie es Sie bei Geschäfts- und Investitionsentscheidungen unterstützten kann, erfahren Sie unter www.sedb.com.

Diese Pressemitteilungen könnten Sie auch interessieren

Weitere Informationen zum Thema "Medizintechnik":

Welche Jobs wird die Künstliche Intelligenz zuerst übernehmen?

Der Ein­satz von Künst­li­cher In­tel­li­genz (KI) bie­tet für Un­ter­neh­men gro­ße Chan­cen – stei­gen­de Um­sät­ze und neue Ar­beits­s­tel­len. Doch der ver­stärk­te Fo­kus auf die smar­te Tech­no­lo­gie könn­te lang­fris­tig auch vie­le Men­schen vom Ar­beits­markt ver­drän­gen.

Weiterlesen

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.


Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.